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CC BY-NC-ND license.Summary Background: Interferon-gamma release assay (IGRA) is popular for detecting
latent tuberculosis infection (LTBI), but its dynamic change is uncertain in high-risk groups
such as dialysis patients.
Methods: Patients undergoing dialysis were prospectively enrolled. The QuantiFERON-TB Gold
In-Tube (QFT-GIT) was used to detect LTBI. After 6 and 12 months, QFT-GIT was repeated to
monitor dynamic changes.
Results: Only 204 of 391 enrolled patients completed the study. The initial QFT-GIT positive rate
of 22.1% decreased to 19.6% after 6months and to 14.2% after 12months. The 6-month reversion
rate was 45.9% while the conversion rate was 7.7%. Sub-population with new QFT-GIT positivity
had 87.5% reversion rate, higher than the 20.8% of patients with persistent QFT-GIT positivity.
The QFT-GIT response was independently associated with persistent QFT-GIT positivity. Using
0.93 IU/ml of the initial QFT-GIT response as the threshold can detect 79% persistent positivity
in 6-month follow-up. Prior TB had a borderline significance for predicting conversion.of Internal Medicine, National Taiwan University Hospital, # 7, Chung-Shan South Road, Taipei 100,
886 2 23582867.
w (J.-Y. Wang).
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530 C.-C. Shu et al.Conclusions: In the dialysis population, reversion and conversion occur frequently within six
months. The QFT-GIT positive population is heterogeneous and sub-populations have different
reversion rates. Higher QFT-GIT positivity threshold can identify patients with persistent QFT-
GIT positivity to prioritize follow-up and LTBI therapy.
ª 2013 The Authors. Published by Elsevier Ltd on behalf of the The British Infection Association.
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Tuberculosis (TB) is one of the most common global infec-
tious diseases with high mortality.1 For preventing further
TB transmission, control should focus on early diagnosis
and treatment of latent TB infection (LTBI).2 Next to TB
contacts, the dialysis population, growing as a consequence
of global ageing, is a known risk group due to attenuated
immunity.3e5 Defined by interferon-gamma release assays
(IGRAs), LTBI has been associated with a decline in renal
function6 and increasing prevalence to around 21e40% in
the dialysis population.7e10
Although IGRAs are currently used to identify LTBI cases
and are useful even in immuno-compromised hosts,11e13 it
should be interpreted carefully because around 7.7% of
IGRA has discordant results in a duplicated test and most
are located in a range near the cut-off value.14 Moreover,
there is a high proportion of IGRA reversion in serial
follow-up studies,15,16 while lower positive IGRA response
is associated with reversion.15 Thus, some investigators sug-
gest using a grey zone instead of a cut-off value to avoid
over-diagnosing LTBI.14,17,18
However, little is known about the impact of impaired
cellular immunity in dialysis on IGRA results.19,20 Longitudi-
nal follow-up and outcome correlation are critical for rede-
fining IGRA positivity in dialysis patients, especially for grey
zone values, to prove clinical efficacy and prioritize re-
sources. This cohort study was conducted to investigate dy-
namic changes in IGRA results and measure reversion and
conversion rates. The clinical significance of IGRA positiv-
ity, as well as its cut-off value, was also studied.
Methods
This prospective cohort study was conducted at National
Taiwan University Hospital, a tertiary referral center in
northern Taiwan, and its branch hospital in southern
Taiwan. The hospital’s institutional review board approved
the study, which was registered in ClinicalTrial.gov
(NCT01311999). All of the participants provided written
informed consent. From March to November 2011, adult pa-
tients (age 20 years) under long-term (>3 months) dialysis
were enrolled. Those with human immuno-deficiency virus
(HIV) infection, liver cirrhosis of Child-Pugh class C, active
tuberculosis within the last three years, or cancer receiving
regular chemotherapy were excluded. Clinical history and
chest radiography were obtained to exclude active TB dis-
ease. Acid-fast smear and mycobacterial culture from three
sputum samples were performed as previously described if
TB was suspected.21
Upon enrollment, QuantiFERON-TB Gold In-Tube assay
(QFT-GIT) (Celestis, Australia) was performed according tothe manufacturer’s instructions (www.cellestis.com). Re-
sults were interpreted as positive, negative, or indetermi-
nate. A three-tube system of QFT-GIT was used, including
the negative control tube, positive control tube (Phytohe-
magglutinin A as the stimulant), and the TB-antigen tube.
After overnight culture, the QFT-GIT response (IU/ml) was
calculated as the interferon-gamma (IFN-g) level in the su-
pernatant of the TB-antigen tube minus that of the nega-
tive control tube. The maximal level of IFN-g detected by
QFT-GIT enzyme-linked immuno-sorbent assay (ELISA) was
10 IU/ml and values greater than this was reported as
10 IU/ml.
The QFT-GIT test was examined at the initial (QFT-GIT1)
and at six (QFT-GIT2) and 12 months (QFT-GIT3) after to
determine dynamic changes. Reversion was defined as the
QFT-GIT result changing from positive to negative in either
QFT-GIT2 or QFT-GIT3, while conversion was defined as the
change from negative to positive.
Sample size calculation
A previous study revealed that around 7.7% of IGRA had
discordant results in a duplicated test.14 Two recent studies
with serial QFT-GIT examinations within one year showed
conversion and reversion in 12.9% of all study subjects.18,22
As such, to have a power of 0.8 and an alpha error of 0.05 in
a one-sided test where the proportion of event cases is
12.9%, which is 5.2% higher than the discordant rate, the
calculated sample size was 193. Assuming a 50% drop-out
rate, at least 386 patients should be enrolled.
Data collection
Clinical and demographic data, including age, sex, co-
morbidity, prior TB history, contact history of TB, respira-
tory and constitutional symptoms, smoking status, and
blood hemoglobin and albumin levels were recorded using
a standardized case report form. Dialysis mode was defined
as its use in the past three months prior to enrollment.
Cough 3 weeks was defined as chronic cough, while
current smoker was defined as those who smoked >100
cigarettes, with the latest time of smoking within one
month prior to the study.23 Chest radiography was inter-
preted by a pulmonologist blinded to the QFT-GIT results.
Statistical analysis
Inter-group differences were analyzed by the student t test
for numerical variables, the ManneWhitney U test for QFT-
GIT response and IFN-g level in the positive control tube,
and the chi-square test for categorical variables. Popula-
tion confidence interval was estimated according to the
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lated to check the correlation between two QFT-GITs.
Multivariate logistic regression analysis was used to
identify factors associated with persistent QFT-GIT positiv-
ity and conversion during follow-up. All potential predictors
were included in the stepwise variable selection procedure.
A two-sided p < 0.05 was considered significant. The
discriminative power of each factor for predicting subse-
quent QFT-GIT positivity was analyzed using the receiver
operating characteristic (ROC) curve and area under the
curve (AUC). The optimal cut-off value was defined as You-
den index. All analyses were performed using the SPSS
(Version 15.0).
Results
A total of 391 patients (mean age, 60.9 years; male, 53%)
under long-term dialysis participated in the QFT-GIT test at
the initial (QFT-GIT1), with 20.3% positivity. Among them,
253 (64.7%) and 204 (52.2%) had follow-up QFT-GIT tests
after 6 (QFT-GIT2) and 12 (QFT-GIT3) months, respectively.
The clinical characteristics and laboratory data were
similar between the 204 cases who completed the three
QFT-GIT tests and the 187 drop-out cases (Online
supplement).
From the baseline characteristics of the 204 cases
(Table 1), 173 were hemodialysis (HD) patients and 31 were
peritoneal dialysis (PD) patients. The mean length of dialysis
was 4.7 years. Among the HD patients, 158 (91.3%) had three
sessions per week while the remaining 15 (8.7%) had two ses-
sions per week. Among the PD patients, 19 (61.3%) had
continuous ambulatory PD and the remaining 12 (38.7%)Table 1 Baseline clinical characteristics of patients according
GIT) response.
Complete cases
(n Z 204)
Reverte
(n Z 25
Age, year 61.2 (12.5) 62.4 (11
Male sex 112 (55%) 14 (56
Current smoker 14 (7%) 4 (16
Dialysis age, year 4.7 (3.8) 5.1 (4.
Malignancy 15 (7%) 1 (4%
Diabetes mellitus 46 (23%) 5 (20
Prior TB history 7 (3%) 1 (4%
Hemoglobin, g/dL 10.3 (1.7) 10.7 (1.
Serum albumin, g/dL 3.92 (0.37) 4.00 (0.
QFT-GIT1 response,b IU/ml 0.40 (0.23) 0.67 (0.
Presence of symptomsc 24 (12%) 2 (8%
Any radiological lesion 78 (38%) 7 (37
QFT-GIT, QuantiFERON-TB Gold In-Tube test; TB, tuberculosis.
Data are no. (%) or mean (standard deviation) except median (inter-q
#Statistical significance (#p < 0.05; ##p < 0.01) between reverters an
with persistent negative QFT-GIT. It was compared by using the stude
QFT-GIT1 response, and chi-square test for categorical variables.
a Reverters are patients who had initial positive QFT-GIT and once ne
vice versa.
b Calculated by the interferon-gamma level in TB-antigen tube min
c Indicated chronic cough, dyspnea, fever, and other constitutionalhad automated PD. During the one-year study period, none
received immuno-suppressants and none had active TB. All
denied TB exposure.
Based on the dynamic change of QFT-GIT results in the
204 patients (Fig. 1), the QFT-GIT1 results were positive in
45 (22.1%) patients, negative in 155 (75.9%), and indetermi-
nate in 4 (2.0%). In QFT-GIT2 and QFT-GIT3, the positive
rate decreased to 19.6% ([24 þ 16]/204) and 14.2%
([19 þ 2þ2 þ 6]/204), respectively. The reversion (positive
to negative) rate was 44.4% (20/45) from QFT-GIT1 to QFT-
GIT2 and 47.5% ([5 þ 14]/[24 þ 16]) from QFT-GIT2 to QFT-
GIT3 (overall 45.9%, 95% CI: 37.0e54.8%). On the other
hand, the conversion (negative to positive) rate was 10.3%
(16/155) and 5.1% ([2 þ 6]/[20 þ 137]) from QFT-GIT1 to
QFT-GIT2 and from QFT-GIT2 to QFT-GIT3, respectively
(overall 7.7%, 95% CI: 5.2e10.2%). The reversion rate in
the next six months was 87.5% (14/16, 95% CI: 71.3e100%)
for a recent converter and 20.8% (5/24, 95% CI:
4.6e37.1%) for persistent positive patients (remote positiv-
ity). As regards QFT-GIT response at each time-point, re-
sults >2.0 IU/ml correlated with persistent positive
pattern rather than the variable pattern or persistent nega-
tive pattern (Fig. 2).
Among QFT-GIT1-positive patients, there was no differ-
ence in age, sex, co-morbidity, and laboratory data be-
tween those with reversion and those with persistent QFT-
GIT positivity, except that the former had lower QFT-GIT
response (calculated by IFN-g level in the supernatant of
TB-antigen tube minus that of negative control tube)
(Table 1). Among the QFT-GIT2-positive patients regardless
of QFT-GIT1 results, QFT-GIT2 response was significantly
higher in the QFT-GIT3-positive than in the QFT-GIT3-the dynamic pattern of QuantiFERON-TB Gold In-Tube (QFT-
rsa
)
Persistent
positive
(n Z 19)
Convertersa
(n Z 22)
Persistent
negative
(n Z 129)
.2) 63.7 (9.9) 62.8 (12.6) 59.7 (13.0)
%) 14 (74%) 11 (50%) 69 (54%)
%) 2 (11%) 2 (9%) 6(5%)
1) 4.1 (3.4) 4.1 (3.4) 4.6 (3.64)
) 1 (5%) 0 12 (9%)
%) 7 (37%) 7 (32%) 24 (19%)
) 2 (11%) 2 (9%) 2 (2%)#
2) 10.8 (1.5) 10.0 (1.4) 10.1 (1.8)
19) 3.98 (0.37) 3.91 (0.38) 3.91 (0.39)
54) 2.85 (3.55)## 0.04 (0.11) 0.02 (0.06)
) 3 (16%) 1 (5%) 18 (14%)
%) 5 (20%) 23 (55%) 49 (38%)
uartile range) in QFT-GIT response.
d those with persistent positive QFT-GIT, or converters and those
nt t test for numerical variables except ManneWhitney U test for
gative change in the following QFT-GIT tests, while converters are
us that in the negative control.
symptoms.
Figure 1 Dynamic changes of QuantiFERON-TB Gold In-Tube (QFT-GIT) results for each time-point according to the study flow-
chart. QFT-R represents QFT-GIT response, by IU/ml (mean  standard deviation).
Figure 2 A linked plot of the QuantiFERON-TB Gold In-Tube
(QFT-GIT) responses. The three letters for group symbols
represent the result of each QFT-GIT test in order (N, negative;
P, positive). The horizontal dash grey line indicates a referen-
tial QFT-GIT response of 0.35 IU/ml.
532 C.-C. Shu et al.negative patients (1.85 vs. 0.57 IU/ml, p < 0.001). The clin-
ical characteristics were similar between those with con-
version and persistent QFT-GIT negative patients, except
that the former had higher proportion of prior TB history
(9% vs. 2%, p Z 0.042) (Table 1). The response in positive
control of QFT-GIT1 was similar regardless subsequent
reversion or conversion. The positive controls of the inde-
terminate results had a significant lower response than
those of positive and negative results (0.16 vs. 9.43 vs.
8.74 IU/ml, p < 0.001).
Patients with different QFT-GIT1 responses had different
conversion and reversion rates (Table 2). The proportion of
conversion was higher in patients with QFT-GIT1 around
0.25e0.34 IU/ml compared to those with QFT-GIT1
<0.25 IU/ml (p Z 0.065 and p Z 0.002 for the change in
QFT-GIT2 and QFT-GIT3, respectively). The proportion of
reversion in patients with QFT-GIT1 0.35e0.80 IU/ml was
higher than those with QFT-GIT1 >0.80 IU/ml (p Z 0.001
and p < 0.001 for QFT-GIT2 and QFT-GIT3, respectively).
There was no significant difference in clinical characteris-
tics between patients with QFT-GIT1 within 0.25e0.80 IU/
ml and the rest. Agreements between results of the first
and the second QFT-GITs and between the first and the
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tively; both p < 0.001).
In multivariate analysis, QFT-GIT1 response was the only
independent factor (odds ratio [OR]: 2.41, 95% CI:
1.23e4.72, per 1 IU/ml increment, p Z 0.010) predicting
persistent QFT-GIT positivity (non-reversion). For QFT-
GIT1-positive patients, ROC curve analysis showed an AUC
of 0.815 (p < 0.001) by QFT-GIT1 response for predicting
persistent QFT-GIT positivity. The optimal cut-off value of
QFT-GIT1 response was 0.93 IU/ml. The QFT-GIT1 response
was <0.93 IU/ml in 67% and 79% of patients with reversion
at 6-month and 12-month follow-up, respectively.
For QFT-GIT2-positive patients, QFT-GIT2 response was
the only independent factor predicting QFT-GIT3 positivity
(OR: 83.77, 95% CI: 4.79e1466.38, per 1 IU/ml increment,
p Z 0.002). The AUC was 0.957 (p < 0.001) by ROC curve
analysis and the optimal cut-off value of QFT-GIT2 was
0.95 IU/ml. No clinical characteristics were independently
associated with QFT-GIT conversion in multivariate anal-
ysis, although prior TB history had borderline significance
(OR: 6.35, 95% CI: 0.846e47.67, p Z 0.072).
Discussion
The present cohort study is the first to focus on dynamic
changes of QFT-GIT in a dialysis population. The overall six-
month reversion rate is high (45.9%), especially in those
with recent positivity (87.5%). The QFT-GIT response is
significantly different between reversion cases and persis-
tently positive patients. A QFT response 0.93 IU/ml
predicts consistent positive QFT-GIT. Conversion is associ-
ated with prior TB and has a rate of 7.7% within 6 months.
The reversion rate of 45.9% within 6 months in dialysis
patients is higher than that in health care workers (33% at
18 weeks) and TB contacts (35% in 6 months) in previous
reports.15,25 This may be due to within-subject variations or
easy negative reversion caused by an immuno-compromised
status.14,19,20,26 With longitudinal follow-up, the 6-month
reversion rate becomes very different between patients
with recent positivity (87.5%) and those with remote posi-
tivity (20.8%). Assuming that reversion occurs as an expo-
nential decay, the half-life of QFT-GIT positivity is around
2 and 18 months, respectively. The proportion of patients
with remote positivity in the QFT-GIT positive population
can be calculated as 62.4% (95% CI: 49.0e90.7%) by the
following formula:Table 2 Conversion and reversion based on different level of t
QFT-GIT1 response,a
IU/ml
Total
numberb
QFT-GIT2
conversion, n (%)
<0.25 145 14 (10%)
0.25e0.34 6 2 (33%)
0.35e0.80 19 e
0.81e3.00 16 e
>3.00 9 e
a QFT-GIT1 response was calculated by interferon-gamma level in t
Initial indeterminate results were not included.
b Total number excluded nine patients with any indeterminate QFTRRoverallZPremote positivity  RRremote positivity þ Precent positivity
 RRrecent positivity;
where RR stands for reversion rate and P is the proportion
of patients.
When overall reversion is balanced by conversion, the
prevalence of QFT-GIT positivity is likewise stable. However,
the decline in QFT-GIT positive rate in this one-year obser-
vational study may be due to a high reversion rate and
underestimation of conversion. The high reversion may be
due to the attenuated cellular immunity in dialysis patients,
leading to rapid reversion after a transient infection.19,20
Explanations for underestimation of conversion include the
“Hawthorne effect” in a non-blinded observation.27 The
study subjects behave better under health education and
closemonitoring during the study period, like smoking cessa-
tion or protecting themselves in public activity, to avoid
LTBI.10 Moreover, despite no significant difference in clinical
characteristics between patients who completed the three
QFT-GITs and the drop-out cases, patients with negative
QFT-GIT1 dropped out more than those with positive QFT-
GIT. Therefore, the number of patients who may convert to
positive in the following QFT-GIT test was reduced.
The current strategy of defining the cut-off value for
IGRA is based on the results of active TB patients and low-
risk healthy subjects.28 Recently, a grey zone of QFT
response has been proposed to replace the cut-off value
of 0.35 IU/ml in the general population.14,18 Although
immuno-compromised hosts without any history of TB con-
tact have a high risk of developing active TB and account
for a major proportion of TB cases, there is no consensus
on whether the result of IGRA should be interpreted as
that in contacts. Consistent with a previous report in health
care workers,15 the present study shows that the QFT-GIT1
response can discriminate between persistent QFT-GIT pos-
itive patients and reversion cases. Persistent positive QFT-
GIT probably indicates patients with LTBI. Although there
is no clinical outcome to correlate QFT-GIT response in
this study, identifying persistent QFT-GIT positive patients
is still of practical importance since it is associated with
the subsequent development of active TB in the dialysis
population, close TB contacts, and users of anti-tumor ne-
crosis factor drugs.8,13,29,30
In patients receiving tumor necrosis factor-alpha (TNF-a)
inhibitor,17 a wider range (0.35e1.0 IU/ml) of QFT-GIT grey
zone than that of the general population (0.35e0.80 IU/ml)he initial QuantiFERON-TB Gold In-Tube (QFT-GIT) response.
QFT-GIT2
reversion, n (%)
QFT-GIT3
conversion, n (%)
QFT-GIT3
reversion, n (%)
e 6 (4%) e
e 2 (33%) e
14 (74%) e 16 (84%)
5 (31%) e 7 (44%)
1 (11%) e 1 (11%)
uberculosis (TB)-antigen tube minus that in the negative control.
-GIT result in the three tests.
534 C.-C. Shu et al.has been proposed.14,18 In the present study, the first
report involving a long-term dialysis population, an optimal
cut-off value for QFT-GIT to identify persistent QFT-GIT
positive patients is 0.93 IU/ml, rather than the current
threshold of 0.35 IU/ml. With 0.93 IU/ml as the new cut-
off value, 67e79% of QFT-GIT positive dialysis patients
can be excluded for follow-up. A higher cut-off value can
possibly pick up a highly selected priority group for
follow-up monitoring and preventive therapy for LTBI if re-
sources are limited. However, future studies to investigate
factors predicting a QFT-GIT result in the grey zone and
long-term follow-up for the development of active TB is
required for risk stratification because definite diagnosis
of LTBI is currently lacking.
The conversion rate of 7.7% within six months for dialysis
patients is higher than that of health care workers
(1.9e2.8%).15,31 As in previous studies, prior TB history
may be a predictor of conversion.10,32 Other reported risk
factors like old age, diabetes mellitus, and cancer are not
significant, probably due to fewer events of conversion in
the present study. Like positive conversion of the tubercu-
lin skin test, the QFT-GIT conversion rate is an estimation of
risk of LTBI, which parallels the local incidence of active
TB.33 In Taiwan, active TB incidence in the dialysis popula-
tion is 300 per 100,000 person-years, which is about four
times the incidence in an age-matched general population
(70.5 per 100,000 person-years).5,34 Because of the high
risk of infection, this special population, especially those
with QFT-GIT response 0.93 IU/ml, should be a priority
group for preventive LTBI therapy. However, a previous
study in TB patients reveals that end-stage renal disease
is an independent risk factor of hepatotoxicity during
anti-TB treatment.35 Further interventional studies to eval-
uate the risk and benefit of preventive therapy in the dial-
ysis population are required.
The present study has some limitations. First, it is an
observational cohort study, so selection bias and placebo
effect may exist. Second, because there is currently no gold
standard for diagnosing LTBI, interpreting the IGRA results
based on correlation with clinical outcome, such as devel-
opment of active TB disease, may be better. Third, this
study was conducted in a tertiary referral center and a
regional hospital. The prevalence of underlying co-
morbidities and LTBI might be higher. Lastly, the number
of conversion is small and the drop-out rate is high. Further
large-scale prospective studies are needed.
In conclusion, patients under long-term dialysis have
high prevalence of QFT-GIT positivity (22.1%) and high QFT-
GIT conversion rate (7.7%) within 6 months. However, 45.9%
revert in the next 6 months. The reversion rate may even be
higher (87.5%) in patients with recent QFT-GIT positivity.
Increasing the diagnostic threshold of QFT-GIT response
from 0.35 to 0.93 IU/ml for dialysis patients may help
identify persistent QFT-GIT positive cases that form the
priority group for follow-up monitoring and possible pre-
ventive therapy.
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